Continuous Intravenous Pumping of Recombinant Human Endostatin (Endostar) Combined with Concurrent R

来源 :第十七届全国临床肿瘤学大会暨2014年CSCO学术年会 | 被引量 : 0次 | 上传用户:liuyr821
下载到本地 , 更方便阅读
声明 : 本文档内容版权归属内容提供方 , 如果您对本文有版权争议 , 可与客服联系进行内容授权或下架
论文部分内容阅读
Objective: Preclinical models have shown that recombinant human endostatin (Endostar) can transiently normalize the tumor vasculature to make it more efficient for oxygen delivery, which provides a treatment window of enhancing tumor radiosensitivity.This study is to evaluate the safety and efficacy of continuous intravenous pumping (CIP) of Endostar combined with standard concurrent radiochemotherapy for unresectable stage Ⅲ Non-small-cell lung cancer (NSCLC).
其他文献
背景:厄洛替尼已获FDA批准用于表皮生长因子受体突变(EGFR MT)的非小细胞肺癌(NSCLC)一线治疗,中位无进展生存期(PFS)为10.4个月.Nivolumab是全人源化IgG4程序性死亡1(PD-1)免疫检查点抑制剂抗体,作为单药治疗晚期NSCLC患者显示了出令人鼓舞的安全性与生存获益.临床前数据支持EGFR路径活化PD-L1表达与免疫逃避在EGFR驱动的肺肿瘤中的作用.本摘要将报告评估
会议
Objective:Programmed death-1 (PD-1) receptor-ligand interaction inhibits T cell activation against tumor cells.Pembro is a potent and highly selective humanized monoclonal antibody against PD-1 design
会议
Objective: Cancer stem cells (CSCs) are believed to cause local recurrence, distant metastasis, radiotherapy and chemotherapy resistance.We hypothesized that genetic variation in CD133 (the official n
会议
Objective: A meta-analysis was recently conducted in East-Asian advanced non-squamous non-small cell lung cancer (nsq-NSCLC) patients based on available individual patient data from three randomized p
会议
Objective: Pemetrexed in combination with platinum has shown better efficacy and less toxicity than other standard first-line chemotherapies for patients with advanced non-squamous non-small cell lung
会议
Objective: To determine the association between visceral pleural invasion (VPI) and post-operative prognosis in early stage non-small cell lung cancer (NSCLC).Method: Between November 2007 and Novembe
会议
Objective: Adenosquamous lung carcinoma (ASC) is a rare type of lung cancer by being histologically mixed adenocarcinoma and squamous cell carcinoma and is very aggressive with a poor prognosis.This s
会议
Objective: A secondary mutation in the EGFR (ie, T790M) and amplification of the c-Met proto-oncogene are the main causes of resistance to EGFR tyrosine kinase inhibitors (eg, gefitinib) in EGFRm+ NSC
会议
Objective: This study was to evaluate the association between single-nucleotide polymorphisms (SNP) in VTI1A gene and the susceptibility to lung cancer in never-smoking Chinese patients, and investiga
会议
Objective:A, an oral, irreversible ErbB family blocker, was compared with GC in 364 Asian pts with EGFR mut positive NSCLC, including 327 pts from China.PFS was significantly prolonged with A vs GC in
会议